BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pegmolesatide (HS-20039) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pegmolesatide (HS-20039)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06946394-954@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pegmolesatide (HS-20039): Phase 4 readout est. (NCT06946394)
DESCRIPTION:Pegmolesatide (HS-20039)\, phase 4\, Chronic Kidney Disease.\nS
 tudy: Use of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switchi
 ng to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HI
 F-PHI\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pegmolesatide-hs-20039#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06946394
URL:https://assetmemo.bio/drug/pegmolesatide-hs-20039#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136792-954@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pegmolesatide (HS-20039): Phase na readout est. (NCT07136792)
DESCRIPTION:Pegmolesatide (HS-20039)\, phase na\, Chronic Kidney Disease.\n
 Study: A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD
 ) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydrox
 ylase Inhibitor (HIF-PHI)\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pegmolesatide-hs-20039#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0713
 6792
URL:https://assetmemo.bio/drug/pegmolesatide-hs-20039#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045155-954@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pegmolesatide (HS-20039): Phase 4 readout est. (NCT07045155)
DESCRIPTION:Pegmolesatide (HS-20039)\, phase 4\, Chronic Kidney Disease.\nS
 tudy: Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term 
 Dialysis\nEstimated primary completion: 30 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pegmolesatide-hs-20039#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07045155
URL:https://assetmemo.bio/drug/pegmolesatide-hs-20039#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
